NCT02578810 PIERS and BIS, sFIT:PIGF, Adrenomedullin
| NCT ID | NCT02578810 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Suez Canal University |
| Condition | Eclampsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 48 participants |
| Start Date | 2016-10 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 48 participants in total. It began in 2016-10 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.
Eligibility Criteria
Inclusion Criteria 1. Pregnancy at any stage (3 trimesters) 2. Eclampsia (Frank eclampsia) will be the crux of the study 3. Pre-eclampsia that is suspected will end up with Frank Eclampsia Exclusion criteria: 1. Any neurological conditions that can alter the electroencephalography like epilepsy 2. Any medical conditions that can alter the electroencephalography like hypoglycemia
Contact & Investigator
Ashraf Dahaba, MD
PRINCIPAL INVESTIGATOR
Guest Professor
Frequently Asked Questions
Who can join the NCT02578810 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Eclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02578810 currently recruiting?
Yes, NCT02578810 is actively recruiting participants. Contact the research team at ashraf.dahaba@medunigraz.at for enrollment information.
Where is the NCT02578810 trial being conducted?
This trial is being conducted at Kuala Lumpur, Malaysia.
Who is sponsoring the NCT02578810 clinical trial?
NCT02578810 is sponsored by Suez Canal University. The principal investigator is Ashraf Dahaba, MD at Guest Professor. The trial plans to enroll 48 participants.